Therapy for influenza and acute respiratory viral infection in young and middle-aged schoolchildren: Effect of Ingavirin® on intoxication, fever, and catarrhal syndromes
The paper presents the clinical results of a double-blind, randomized, placebo-controlled multicenter phase III study evaluating the clinical efficacy and safety of Ingavirin® capsules 30 mg at a daily dose of 60 mg for the treatment of influenza and other acute respiratory viral infections (ARVI) i...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ltd. “The National Academy of Pediatric Science and Innovation”
2016-04-01
|
| Series: | Rossijskij Vestnik Perinatologii i Pediatrii |
| Subjects: | |
| Online Access: | https://www.ped-perinatology.ru/jour/article/view/314 |
| _version_ | 1797875330646540288 |
|---|---|
| author | I. M. Farber N. A. Geppe D. V. Reikhart V. E. Nebolsin V. S. Arnautov A. A. Globenko |
| author_facet | I. M. Farber N. A. Geppe D. V. Reikhart V. E. Nebolsin V. S. Arnautov A. A. Globenko |
| author_sort | I. M. Farber |
| collection | DOAJ |
| description | The paper presents the clinical results of a double-blind, randomized, placebo-controlled multicenter phase III study evaluating the clinical efficacy and safety of Ingavirin® capsules 30 mg at a daily dose of 60 mg for the treatment of influenza and other acute respiratory viral infections (ARVI) in 7–12-year-old children.The study included 310 children of both sexes. The study participants took Ingavirin® 60 mg/day or placebo for 5 days. The drug was shown to be effective in normalizing temperature and alleviating intoxication and catarrhal syndromes just at day 3 of therapy. Ingavirin® was demonstrated to considerably reduce the risk of bacterial complications of ARVI/influenza, which require antibiotic therapy, which is important for clinical use in children. This clinical trial has shown the high safety and tolerance of the drug. Ingavirin® contributes to accelerated virus elimination, shorter disease duration, and lower risk of complications. |
| first_indexed | 2024-04-10T01:44:53Z |
| format | Article |
| id | doaj.art-bf96c1553def461f913bd0f6f9a26ef3 |
| institution | Directory Open Access Journal |
| issn | 1027-4065 2500-2228 |
| language | Russian |
| last_indexed | 2024-04-10T01:44:53Z |
| publishDate | 2016-04-01 |
| publisher | Ltd. “The National Academy of Pediatric Science and Innovation” |
| record_format | Article |
| series | Rossijskij Vestnik Perinatologii i Pediatrii |
| spelling | doaj.art-bf96c1553def461f913bd0f6f9a26ef32023-03-13T09:12:42ZrusLtd. “The National Academy of Pediatric Science and Innovation”Rossijskij Vestnik Perinatologii i Pediatrii1027-40652500-22282016-04-0161211512010.21508/1027-4065-2016-61-2-115-120305Therapy for influenza and acute respiratory viral infection in young and middle-aged schoolchildren: Effect of Ingavirin® on intoxication, fever, and catarrhal syndromesI. M. Farber0N. A. Geppe1D. V. Reikhart2V. E. Nebolsin3V. S. Arnautov4A. A. Globenko5ГБОУ ВПО «Первый московский государственный медицинский университет имени И.М. Сеченова»ГБОУ ВПО «Первый московский государственный медицинский университет имени И.М. Сеченова»ГБОУ ВПО «Первый московский государственный медицинский университет имени И.М. Сеченова»ООО «Фарминтерпрайсез»ОАО «Валента Фарм»ОАО «Валента Фарм»The paper presents the clinical results of a double-blind, randomized, placebo-controlled multicenter phase III study evaluating the clinical efficacy and safety of Ingavirin® capsules 30 mg at a daily dose of 60 mg for the treatment of influenza and other acute respiratory viral infections (ARVI) in 7–12-year-old children.The study included 310 children of both sexes. The study participants took Ingavirin® 60 mg/day or placebo for 5 days. The drug was shown to be effective in normalizing temperature and alleviating intoxication and catarrhal syndromes just at day 3 of therapy. Ingavirin® was demonstrated to considerably reduce the risk of bacterial complications of ARVI/influenza, which require antibiotic therapy, which is important for clinical use in children. This clinical trial has shown the high safety and tolerance of the drug. Ingavirin® contributes to accelerated virus elimination, shorter disease duration, and lower risk of complications.https://www.ped-perinatology.ru/jour/article/view/314детиорвигриппосложнениялечениеингавирин®имидазолилэтанамид пентандиовой кислоты |
| spellingShingle | I. M. Farber N. A. Geppe D. V. Reikhart V. E. Nebolsin V. S. Arnautov A. A. Globenko Therapy for influenza and acute respiratory viral infection in young and middle-aged schoolchildren: Effect of Ingavirin® on intoxication, fever, and catarrhal syndromes Rossijskij Vestnik Perinatologii i Pediatrii дети орви грипп осложнения лечение ингавирин® имидазолилэтанамид пентандиовой кислоты |
| title | Therapy for influenza and acute respiratory viral infection in young and middle-aged schoolchildren: Effect of Ingavirin® on intoxication, fever, and catarrhal syndromes |
| title_full | Therapy for influenza and acute respiratory viral infection in young and middle-aged schoolchildren: Effect of Ingavirin® on intoxication, fever, and catarrhal syndromes |
| title_fullStr | Therapy for influenza and acute respiratory viral infection in young and middle-aged schoolchildren: Effect of Ingavirin® on intoxication, fever, and catarrhal syndromes |
| title_full_unstemmed | Therapy for influenza and acute respiratory viral infection in young and middle-aged schoolchildren: Effect of Ingavirin® on intoxication, fever, and catarrhal syndromes |
| title_short | Therapy for influenza and acute respiratory viral infection in young and middle-aged schoolchildren: Effect of Ingavirin® on intoxication, fever, and catarrhal syndromes |
| title_sort | therapy for influenza and acute respiratory viral infection in young and middle aged schoolchildren effect of ingavirin r on intoxication fever and catarrhal syndromes |
| topic | дети орви грипп осложнения лечение ингавирин® имидазолилэтанамид пентандиовой кислоты |
| url | https://www.ped-perinatology.ru/jour/article/view/314 |
| work_keys_str_mv | AT imfarber therapyforinfluenzaandacuterespiratoryviralinfectioninyoungandmiddleagedschoolchildreneffectofingavirinonintoxicationfeverandcatarrhalsyndromes AT nageppe therapyforinfluenzaandacuterespiratoryviralinfectioninyoungandmiddleagedschoolchildreneffectofingavirinonintoxicationfeverandcatarrhalsyndromes AT dvreikhart therapyforinfluenzaandacuterespiratoryviralinfectioninyoungandmiddleagedschoolchildreneffectofingavirinonintoxicationfeverandcatarrhalsyndromes AT venebolsin therapyforinfluenzaandacuterespiratoryviralinfectioninyoungandmiddleagedschoolchildreneffectofingavirinonintoxicationfeverandcatarrhalsyndromes AT vsarnautov therapyforinfluenzaandacuterespiratoryviralinfectioninyoungandmiddleagedschoolchildreneffectofingavirinonintoxicationfeverandcatarrhalsyndromes AT aaglobenko therapyforinfluenzaandacuterespiratoryviralinfectioninyoungandmiddleagedschoolchildreneffectofingavirinonintoxicationfeverandcatarrhalsyndromes |